Propofol as an antiemetic for managing post-operative nausea and vomiting in parturient undergoing cesarean section under spinal anesthesia: a randomized control trial with implications for oncology

Abstract

Author(s): Myasar Jasim Mohammed, Inaam Faisal Mohammed, Saja Abbood Khaleel

Many women who undergo caesarean section suffer from nausea and vomiting symptoms during and after surgeries. This study aims to assess the ability of propofol to reduce the severity of nausea and vomiting symptoms after Caesarean Section (CS). Randomized clinical trial was conducted on ninety parturients from January to December 2022 at the obstetric unit (single-center) of AL–Shafaa private Hospital Diyala, Iraq. Two equal groups were compared; the first group received continuous 1% propofol infusion (10 mg/mL) and the second group received placebo (0.9% saline). Results showed statistically significant difference between the control group (saline) and the antiemetic medication (propofol) in postcesarean nausea (relative risk 0.514; 95% CI 17.3%–39.6%; p=0.003) and vomiting incidence (relative risk 0.695; 95% CI, 4.39%–22.5%; p=0.014), respectively. Moreover, the request for ondansetron was lower in propofol group (four patients) than the placebo group (ten patients) with a relative risk of 0.437; 95% CI, 3.52%–21.57%; p=0.074. Findings of this study support the previous studies about the effectiveness of propofol as antiemetic to lower the incidence of post-operative nausea and vomiting.

Share this article